BTN3A1 and neoplasm: In addition to direct tumor‐killing and antigen presentation, we also uncover another synergistic mechanism of pVγ9Vδ2/αβ T cell combinatorial therapy, through which pVγ9Vδ2 T cells reverse BTN3A1‐mediated αβ T cell inhibition by competitively binding to BTN3A1 expressed by CC cells (Figure 7).